In recent years, the development of highly potent molecules has become more frequent, and around 25% of the components that are being developed are classified as potent.

As older products reach patent expiry, generic-drug companies are also moving into this space, increasing the demand for capability and capacity to manufacture highly potent Active Pharmaceutical Ingredients (APIs).

High potent APIs are defined as a pharmacologically API or intermediate with biological activity at approximately 150µg/kg of body weight or below in humans (therapeutic daily dose at or below 10mg), with an occupational exposure limit (OEL) at or below 10µg/m³ of air as an eight-hour time-weighted average.

Download the free whitepaper for more information.